Lataa...
3-Iodothyronamine and Derivatives: New Allies Against Metabolic Syndrome?
In the two decades since its discovery, a large body of evidence has amassed to highlight the potential of 3-iodothyronamine (T1AM) as an antiobesity drug, whose pleiotropic signaling actions profoundly impact energy metabolism. In the present review, we recapitulate the most relevant properties of...
Tallennettuna:
| Julkaisussa: | Int J Mol Sci |
|---|---|
| Päätekijät: | , , , |
| Aineistotyyppi: | Artigo |
| Kieli: | Inglês |
| Julkaistu: |
MDPI
2020
|
| Aiheet: | |
| Linkit: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7139928/ https://ncbi.nlm.nih.gov/pubmed/32183490 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3390/ijms21062005 |
| Tagit: |
Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!
|